Rundu Pharma: The application for the listing of the chemical raw material drug of sodium chloride compound of glucosamine sulfate has been approved
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Glucosamine Sulfate Sodium Chloride Compound (hereinafter referred to as "this product"). This product is suitable for the treatment of primary and secondary osteoarthritis. The approval of this product further enriches the company's product categories, enhances the company's market competitiveness, and has a positive impact on the company's future operating performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments